Allergan Must Face FCA Claims Over Dementia Drug Patents
A California federal judge rejected Allergan's bid to dodge a False Claims Act lawsuit Friday, finding the patent attorney behind the suit sufficiently alleged that the pharmaceutical company fraudulently obtained two...To view the full article, register now.
Already a subscriber? Click here to view full article